JP7498882B2 - 異常タンパク質蓄積性神経変性疾患の治療剤 - Google Patents

異常タンパク質蓄積性神経変性疾患の治療剤 Download PDF

Info

Publication number
JP7498882B2
JP7498882B2 JP2021562745A JP2021562745A JP7498882B2 JP 7498882 B2 JP7498882 B2 JP 7498882B2 JP 2021562745 A JP2021562745 A JP 2021562745A JP 2021562745 A JP2021562745 A JP 2021562745A JP 7498882 B2 JP7498882 B2 JP 7498882B2
Authority
JP
Japan
Prior art keywords
adrenomedullin
group
unsubstituted
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562745A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021112220A1 (https=
JPWO2021112220A5 (https=
Inventor
和雄 北村
雅典 福島
秀雄 西村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miyazaki NUC
Original Assignee
University of Miyazaki NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miyazaki NUC filed Critical University of Miyazaki NUC
Publication of JPWO2021112220A1 publication Critical patent/JPWO2021112220A1/ja
Publication of JPWO2021112220A5 publication Critical patent/JPWO2021112220A5/ja
Application granted granted Critical
Publication of JP7498882B2 publication Critical patent/JP7498882B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021562745A 2019-12-05 2020-12-04 異常タンパク質蓄積性神経変性疾患の治療剤 Active JP7498882B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019220695 2019-12-05
JP2019220695 2019-12-05
PCT/JP2020/045235 WO2021112220A1 (ja) 2019-12-05 2020-12-04 異常タンパク質蓄積性神経変性疾患の治療剤

Publications (3)

Publication Number Publication Date
JPWO2021112220A1 JPWO2021112220A1 (https=) 2021-06-10
JPWO2021112220A5 JPWO2021112220A5 (https=) 2022-07-29
JP7498882B2 true JP7498882B2 (ja) 2024-06-13

Family

ID=76221768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562745A Active JP7498882B2 (ja) 2019-12-05 2020-12-04 異常タンパク質蓄積性神経変性疾患の治療剤

Country Status (2)

Country Link
JP (1) JP7498882B2 (https=)
WO (1) WO2021112220A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532682A (ja) 2011-11-03 2014-12-08 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリエチレングリコールベースのアドレノメデュリンのプロドラッグおよびその使用
WO2017047788A1 (ja) 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) * 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
CN106164088B (zh) * 2014-03-20 2021-11-23 国立大学法人宫崎大学 长效肾上腺髓质素衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532682A (ja) 2011-11-03 2014-12-08 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリエチレングリコールベースのアドレノメデュリンのプロドラッグおよびその使用
WO2017047788A1 (ja) 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田中正明 他，アドレノメデュリン‐RAMP2系はヒト網膜色素上皮細胞の上皮間葉転換を抑制する，日本眼科学会雑誌，2019年03月13日，Vol.123 臨時増刊号，Page.263

Also Published As

Publication number Publication date
JPWO2021112220A1 (https=) 2021-06-10
WO2021112220A1 (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
EP2099468B1 (en) Methods of use of trk receptor modulators
JP2005524649A (ja) Ｍｃ４−ｒアゴニストの鼻腔内投与
HUP0004581A2 (hu) Eljárás csonttérfogat növelésére nem természetes előfordulású FP szelektív agonisták alkalmazásával
JP2010501597A (ja) 正のアロステリックａｍｐａ受容体モジュレーターを用いて呼吸抑制を阻害する方法
EP2863935B1 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma
JP2021510731A (ja) ペプチドおよびその使用
US20250367181A1 (en) Centrally-Active Ghrelin Agonist and Medical Uses Thereof
JP2025161811A (ja) タウオパチーを処置するためのペプチド組成物及び方法
DE10139410A1 (de) Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US20230241231A1 (en) Central nervous system delivery of psilocybin
WO2019126256A1 (en) Supramolecular hydrogel applications to the carotid bodies
ES2935705T3 (es) Un ligando del receptor GABA A
JP7498882B2 (ja) 異常タンパク質蓄積性神経変性疾患の治療剤
JP6262661B2 (ja) 筋萎縮性側索硬化症治療剤
US20040248816A1 (en) Treatment of migraine
US10842845B2 (en) Oxytocin improves treatment of obstructive sleep apnea
US20080096870A1 (en) Methods and Materials for Treating Mental Illness
JP2007523148A (ja) 疼痛の軽減方法
FR3077201A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
CN105592849A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
JP2022104448A (ja) 認知症治療薬
KR20180102091A (ko) 당뇨병의 치료를 위한 약제학적 제제
CA2520930A1 (en) Use of the hydrochloride of the active ingredient base 1-[n<sp>2</sp>-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines
WO2024142211A1 (ja) 認知症治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220601

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240402

R150 Certificate of patent or registration of utility model

Ref document number: 7498882

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150